Brit J Cancer:二甲双胍联合伊立替康治疗难治性大肠癌疗效分析

2021-01-06 MedSci原创 MedSci原创

难治性CRC患者采用二甲双胍加伊立替康治疗可达到疾病控制。需要进一步的优化腹泻控制试验来证实这些结果。

难治性大肠癌(CRC)患者几乎没有有效的治疗选择。近日,肿瘤学领域权威杂志British Journal of Cancer上发表了一篇研究文章,该试验旨在检验二甲双胍和伊立替康组合治疗对这类患者的疗效。

研究人员进行了一项2期单组试验,患者每天口服二甲双胍2500mg,静脉注射伊立替康125μmg/m2,每周一次。该研究的主要终点是在12周时根据《1.1版实体瘤反应评估标准》确定的疾病控制率。

在2015年12月至2018年1月期间,研究人员共招募了41名患者。12周内有17名患者(41%)达到了疾病控制的主要终点。参与者中位无进展生存期为3.3个月(95%CI为2.0-4.5个月),参与者中位总生存期为8.4个月(95%CI为5.9-10.8个月)。在多变量模型中,RAS突变状态和12周时的疾病控制都影响了参与者总生存率(HR为2.28,95%CI为1.12-4.7,p=0.02;HR为0.21,95%CI为0.08-0.5,p=0.001)。最常见的不良事件为腹泻(29.2%的参与者为3级腹泻)。

在该试验中,难治性CRC患者采用二甲双胍加伊立替康治疗可达到疾病控制。需要进一步的优化腹泻控制试验来证实这些结果。

原始出处:

Arinilda Campos Bragagnoli.et al.Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial.Brit J Cancer.2021.https://www.nature.com/articles/s41416-020-01208-6

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1647289, encodeId=8dfb164e2893e, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Wed Jan 06 13:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528723, encodeId=d9731528e23cb, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Jan 08 03:42:45 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914180, encodeId=3edd91418054, content=病例数太少了吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84622224068, createdName=寻山郎中, createdTime=Wed Jan 06 20:40:40 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914270, encodeId=2b679142e049, content=内容丰富,已学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201225/6e1ef4f864494d0284b9282bc4cafc19/f7f10a42767b46c9823f11c34f905873.jpg, createdBy=145f5447474, createdName=ms6000001700483633, createdTime=Thu Jan 07 04:31:43 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032754, encodeId=01411032e54c5, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jan 06 15:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041563, encodeId=6c79104156322, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 06 15:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914060, encodeId=e865914060dc, content=<a href='/topic/show?id=18c6256e1ba' target=_blank style='color:#2F92EE;'>#伊立替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25671, encryptionId=18c6256e1ba, topicName=伊立替康)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jan 06 12:51:54 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914059, encodeId=de20914059c5, content=<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>用于<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>,作为辅助治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=78692, encryptionId=493ae869206, topicName=结直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jan 06 12:50:55 CST 2021, time=2021-01-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1647289, encodeId=8dfb164e2893e, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Wed Jan 06 13:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528723, encodeId=d9731528e23cb, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Jan 08 03:42:45 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914180, encodeId=3edd91418054, content=病例数太少了吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84622224068, createdName=寻山郎中, createdTime=Wed Jan 06 20:40:40 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914270, encodeId=2b679142e049, content=内容丰富,已学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201225/6e1ef4f864494d0284b9282bc4cafc19/f7f10a42767b46c9823f11c34f905873.jpg, createdBy=145f5447474, createdName=ms6000001700483633, createdTime=Thu Jan 07 04:31:43 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032754, encodeId=01411032e54c5, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jan 06 15:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041563, encodeId=6c79104156322, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 06 15:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914060, encodeId=e865914060dc, content=<a href='/topic/show?id=18c6256e1ba' target=_blank style='color:#2F92EE;'>#伊立替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25671, encryptionId=18c6256e1ba, topicName=伊立替康)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jan 06 12:51:54 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914059, encodeId=de20914059c5, content=<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>用于<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>,作为辅助治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=78692, encryptionId=493ae869206, topicName=结直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jan 06 12:50:55 CST 2021, time=2021-01-06, status=1, ipAttribution=)]
    2021-01-08 freve
  3. [GetPortalCommentsPageByObjectIdResponse(id=1647289, encodeId=8dfb164e2893e, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Wed Jan 06 13:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528723, encodeId=d9731528e23cb, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Jan 08 03:42:45 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914180, encodeId=3edd91418054, content=病例数太少了吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84622224068, createdName=寻山郎中, createdTime=Wed Jan 06 20:40:40 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914270, encodeId=2b679142e049, content=内容丰富,已学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201225/6e1ef4f864494d0284b9282bc4cafc19/f7f10a42767b46c9823f11c34f905873.jpg, createdBy=145f5447474, createdName=ms6000001700483633, createdTime=Thu Jan 07 04:31:43 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032754, encodeId=01411032e54c5, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jan 06 15:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041563, encodeId=6c79104156322, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 06 15:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914060, encodeId=e865914060dc, content=<a href='/topic/show?id=18c6256e1ba' target=_blank style='color:#2F92EE;'>#伊立替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25671, encryptionId=18c6256e1ba, topicName=伊立替康)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jan 06 12:51:54 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914059, encodeId=de20914059c5, content=<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>用于<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>,作为辅助治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=78692, encryptionId=493ae869206, topicName=结直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jan 06 12:50:55 CST 2021, time=2021-01-06, status=1, ipAttribution=)]
    2021-01-06 寻山郎中

    病例数太少了吧

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1647289, encodeId=8dfb164e2893e, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Wed Jan 06 13:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528723, encodeId=d9731528e23cb, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Jan 08 03:42:45 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914180, encodeId=3edd91418054, content=病例数太少了吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84622224068, createdName=寻山郎中, createdTime=Wed Jan 06 20:40:40 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914270, encodeId=2b679142e049, content=内容丰富,已学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201225/6e1ef4f864494d0284b9282bc4cafc19/f7f10a42767b46c9823f11c34f905873.jpg, createdBy=145f5447474, createdName=ms6000001700483633, createdTime=Thu Jan 07 04:31:43 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032754, encodeId=01411032e54c5, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jan 06 15:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041563, encodeId=6c79104156322, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 06 15:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914060, encodeId=e865914060dc, content=<a href='/topic/show?id=18c6256e1ba' target=_blank style='color:#2F92EE;'>#伊立替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25671, encryptionId=18c6256e1ba, topicName=伊立替康)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jan 06 12:51:54 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914059, encodeId=de20914059c5, content=<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>用于<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>,作为辅助治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=78692, encryptionId=493ae869206, topicName=结直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jan 06 12:50:55 CST 2021, time=2021-01-06, status=1, ipAttribution=)]
    2021-01-07 ms6000001700483633

    内容丰富,已学习。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1647289, encodeId=8dfb164e2893e, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Wed Jan 06 13:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528723, encodeId=d9731528e23cb, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Jan 08 03:42:45 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914180, encodeId=3edd91418054, content=病例数太少了吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84622224068, createdName=寻山郎中, createdTime=Wed Jan 06 20:40:40 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914270, encodeId=2b679142e049, content=内容丰富,已学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201225/6e1ef4f864494d0284b9282bc4cafc19/f7f10a42767b46c9823f11c34f905873.jpg, createdBy=145f5447474, createdName=ms6000001700483633, createdTime=Thu Jan 07 04:31:43 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032754, encodeId=01411032e54c5, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jan 06 15:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041563, encodeId=6c79104156322, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 06 15:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914060, encodeId=e865914060dc, content=<a href='/topic/show?id=18c6256e1ba' target=_blank style='color:#2F92EE;'>#伊立替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25671, encryptionId=18c6256e1ba, topicName=伊立替康)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jan 06 12:51:54 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914059, encodeId=de20914059c5, content=<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>用于<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>,作为辅助治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=78692, encryptionId=493ae869206, topicName=结直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jan 06 12:50:55 CST 2021, time=2021-01-06, status=1, ipAttribution=)]
    2021-01-06 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1647289, encodeId=8dfb164e2893e, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Wed Jan 06 13:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528723, encodeId=d9731528e23cb, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Jan 08 03:42:45 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914180, encodeId=3edd91418054, content=病例数太少了吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84622224068, createdName=寻山郎中, createdTime=Wed Jan 06 20:40:40 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914270, encodeId=2b679142e049, content=内容丰富,已学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201225/6e1ef4f864494d0284b9282bc4cafc19/f7f10a42767b46c9823f11c34f905873.jpg, createdBy=145f5447474, createdName=ms6000001700483633, createdTime=Thu Jan 07 04:31:43 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032754, encodeId=01411032e54c5, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jan 06 15:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041563, encodeId=6c79104156322, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 06 15:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914060, encodeId=e865914060dc, content=<a href='/topic/show?id=18c6256e1ba' target=_blank style='color:#2F92EE;'>#伊立替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25671, encryptionId=18c6256e1ba, topicName=伊立替康)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jan 06 12:51:54 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914059, encodeId=de20914059c5, content=<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>用于<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>,作为辅助治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=78692, encryptionId=493ae869206, topicName=结直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jan 06 12:50:55 CST 2021, time=2021-01-06, status=1, ipAttribution=)]
    2021-01-06 misszhang

    二甲双胍,神药!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1647289, encodeId=8dfb164e2893e, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Wed Jan 06 13:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528723, encodeId=d9731528e23cb, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Jan 08 03:42:45 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914180, encodeId=3edd91418054, content=病例数太少了吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84622224068, createdName=寻山郎中, createdTime=Wed Jan 06 20:40:40 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914270, encodeId=2b679142e049, content=内容丰富,已学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201225/6e1ef4f864494d0284b9282bc4cafc19/f7f10a42767b46c9823f11c34f905873.jpg, createdBy=145f5447474, createdName=ms6000001700483633, createdTime=Thu Jan 07 04:31:43 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032754, encodeId=01411032e54c5, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jan 06 15:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041563, encodeId=6c79104156322, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 06 15:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914060, encodeId=e865914060dc, content=<a href='/topic/show?id=18c6256e1ba' target=_blank style='color:#2F92EE;'>#伊立替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25671, encryptionId=18c6256e1ba, topicName=伊立替康)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jan 06 12:51:54 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914059, encodeId=de20914059c5, content=<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>用于<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>,作为辅助治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=78692, encryptionId=493ae869206, topicName=结直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jan 06 12:50:55 CST 2021, time=2021-01-06, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1647289, encodeId=8dfb164e2893e, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Wed Jan 06 13:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1528723, encodeId=d9731528e23cb, content=<a href='/topic/show?id=74b798601a1' target=_blank style='color:#2F92EE;'>#难治性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98601, encryptionId=74b798601a1, topicName=难治性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1ef11916292, createdName=freve, createdTime=Fri Jan 08 03:42:45 CST 2021, time=2021-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914180, encodeId=3edd91418054, content=病例数太少了吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84622224068, createdName=寻山郎中, createdTime=Wed Jan 06 20:40:40 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914270, encodeId=2b679142e049, content=内容丰富,已学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201225/6e1ef4f864494d0284b9282bc4cafc19/f7f10a42767b46c9823f11c34f905873.jpg, createdBy=145f5447474, createdName=ms6000001700483633, createdTime=Thu Jan 07 04:31:43 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032754, encodeId=01411032e54c5, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Wed Jan 06 15:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041563, encodeId=6c79104156322, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Jan 06 15:42:45 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914060, encodeId=e865914060dc, content=<a href='/topic/show?id=18c6256e1ba' target=_blank style='color:#2F92EE;'>#伊立替康#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25671, encryptionId=18c6256e1ba, topicName=伊立替康)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jan 06 12:51:54 CST 2021, time=2021-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=914059, encodeId=de20914059c5, content=<a href='/topic/show?id=ce9d239823b' target=_blank style='color:#2F92EE;'>#二甲双胍#</a>用于<a href='/topic/show?id=493ae869206' target=_blank style='color:#2F92EE;'>#结直肠癌#</a>,作为辅助治疗, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23982, encryptionId=ce9d239823b, topicName=二甲双胍), TopicDto(id=78692, encryptionId=493ae869206, topicName=结直肠癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Jan 06 12:50:55 CST 2021, time=2021-01-06, status=1, ipAttribution=)]
    2021-01-06 lovetcm

    #二甲双胍#用于#结直肠癌#,作为辅助治疗

    0

相关资讯

Mol Cancer Ther:二甲双胍能够合成致死代谢靶向雄激素缺乏的前列腺癌细胞

雄激素阻断疗法(ADT)会诱导前列腺癌(PC)细胞的易感性,使其容易受到协同治疗的影响和增加细胞死亡。衰老导致细胞周期停止,但细胞仍有活力。

JAHA:二甲双胍治疗肺动脉高压的II期临床试验

在这项单中心、开放标签的II期研究中,二甲双胍对PAH患者安全且耐受性良好。探索性分析表明,二甲双胍可能与改善的RV分数面积变化有关。

Brit J Cancer:二甲双胍与肺癌患者生存率的关系

二甲双胍可提高LC患者生存率,尤其是区域性SCC患者的LCSS。需要进一步的前瞻性研究来明确二甲双胍在LC治疗中的作用。

Clin Trans Gastroenterology:2型糖尿病使用二甲双胍可以减少胃肠道癌症的发生风险

关于二甲双胍对胃肠道癌症发展的影响,临床研究产生了矛盾的研究结果。本项研究的目的是探究新诊断为未经药物治疗的2型糖尿病患者中二甲双胍的使用与胃癌,结肠癌,肝癌和胰腺癌发生之间的关系。

Nat Metab:“神药”还是“毒药”,二甲双胍缩短衰老生物体寿命

研究人员在Nature Metabolism杂志发文,其发现,在线虫和人类原代细胞中,当在晚期提供二甲双胍时,二甲双胍会缩短寿命,这与它在年轻生物体中的积极作用相反。

JTO:阿司匹林、他汀类药物和二甲双胍与肺癌风险和相关死亡率的关系

本研究的目的是使用基于人群的全国队列数据研究阿司匹林,二甲双胍和他汀类药物与肺癌风险和死亡率的关系。